...and this one statement sent tingling up my leg....
"This is an important milestone for Cellceutix and for the field of infectious diseases," said Leo Ehrlich, the company's CEO. "There is no other antibiotic with these properties, which can treat infection and potentially decrease the burden of antibiotic resistance. Resistance, the antibiotic slayer. We are now in the process of manufacturing 30 kg of Brilacidin for future clinical trials which we plan for multiple forms of serious infections."
News 
Market Data 
Discover 
